Anaphore, Inc.

Abbott Gmbh & Co Kg

Hoffmann-la Roche Inc.

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Denzyme Aps

Thor Las Holtet

Geertruida Machteld Veldman

Boris Labkovsky

Jochen G Salfeld

Zehra Kaymakcalan

Michael White

Michael Roguska

Paul Sakorafas

Nicholas W Warne

Subhashis Banerjee

Angela Widom

Daniel Edward Tracey

Elaine Joy Derbyshire

John Gawain Elvin

Sara Carmen

Michael Paskind

Alexander Robert Duncan

Sarah Leila Du Fou

Stuart Friedrich

Stephen Smith

Amy Venturini

Michael Etzerodt

Niels Jonas Heilskov Graversen

Angela Myles

Hans Christian Thøgersen

Jette Sandholm Kastrup

Bettina Bryde Nielsen

Angela Kantor

Ingrid Kjøller Larsen

Josephus Dirk Nieland

Helle Krogh Ottow

Mette Munch

Mikkel Holmen Andersen

Hans Christian Thogersen

Ingrid Kjoller Larsen

Christian Tho Slashedgersen

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs.

Trimerising module

The present invention provides novel polypeptides having the scaffold structure of a C-type lectin-like domain (CTLD) and a randomized loop region for specifically binding a variety of target compounds and also provides nucleic acids encoding the polypeptides. The present invention further provides combinatorial CTLD libraries, methods for constructing the libraries, and methods for screening the libraries to identify and isolate the novel CTLD polypeptides. Specifically, the invention provides libraries of nucleic acids encoding polypeptides having a scaffold CTLD with a randomized loop region, as well as nucleic acid sequences, vectors, and methods for preparing and expressing the libraries. Exemplary nucleic acids useful in the combinatorial libraries are derived from tetranectin and other proteins having a CTLD.

Combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods for inhibiting the activity of the P40 subunit of human IL-12

TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy. The polypeptides comprise a TNF binding domain having the amino acid sequence KRWS-RYF (SEQ ID NO:1). Also provided are methods of preparing the polypeptides of the invention. The polypeptides may be used for the preparation of pharmaceutical compositions, and for treatment of a subject having a pathology mediated by TNF, such as treatment of rheumatoid arthritis.

TNF antagonists

Human antibodies that bind human IL-12

Human antibodies that bind human IL-12 and methods for producing

A novel, generally applicable method for producing correctly folded proteins from a mixture of misfolded proteins, e.g. bacterial inclusion-body aggregates. A major new aspect of the method is that over-all efficiency is achieved by subjecting proteins to a time-sequence of multiple denaturation-renaturation cycles, resulting in gradual accumulation of the correctly folded protein. The method has proven efficient for a variety of recombinant proteins. Also provided are novel encrypted recognition sites for bovine coagulation factor X.sub.a. The encrypted recognition sites described may be activated in vitro by controlled oxidation or by reversible derivatization of cysteine residues and thereby generate new cleavage sites for factor X.sub.a. Two new recombinant serine protease exhibiting narrow substrate specificity for factor X.sub.a recognition sites are also provided. They may replace natural coagulation factor X.sub.a for cleavage of chimeric proteins.

Iterative method of at least five cycles for the refolding of proteins

Growing community of inventors

Ronde, Denmark

Thor Las Holtet